𝐓𝐚𝐢𝐰𝐚𝐧 𝐄𝐚𝐫𝐥𝐲 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐫𝐢𝐯𝐞𝐫𝐬, 𝐑𝐞𝐬𝐭𝐫𝐚𝐢𝐧𝐭𝐬, 𝐚𝐧𝐝 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐓𝐚𝐢𝐰𝐚𝐧 𝐄𝐚𝐫𝐥𝐲 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 is predicted to reach USD 117.04 million with a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟓.𝟐𝟐% 𝐭𝐢𝐥𝐥 𝟐𝟎𝟑𝟎. Early toxicity testing is a crucial procedure that entails the assessment of potential harmful effects or toxicity associated with drugs, chemicals, or other substances during their initial developmental stages. 𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 : 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 : Taiwan has become a key location for clinical trials in Asia due to its well-established healthcare system, skilled workforce, and regulatory environment. As clinical trials increase, the need for preclinical testing—including early toxicity testing—grows to ensure that drug candidates are safe before progressing to human trials. 𝐆𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐎𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 (𝐂𝐑𝐎𝐬) : Taiwan’s growing CRO industry plays a key role in providing preclinical testing services to both domestic and international clients. Many pharmaceutical, biotech, and chemical companies are outsourcing early-stage toxicity testing to CROs in Taiwan, driven by cost-effectiveness and access to specialized expertise. https://www.nextmsc.com/report/taiwan-early-toxicity-testing-market